Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: ASOS CEO Sells GBP20 Million In Shares

Fri, 30th Jan 2015 12:45

Director Dealings Summary - Week Ended January 30        
Company Name Position Buy or Sell Number of Shares Resulting Holding *Note
3i Group Caroline Banszky Non-Executive Director Buy 6,000 undisclosed Same day as dilluted net aset value increased 5%
ASOS Nick Robertson CEO Sold 744,600 7 million Deal worth GBP20 million
Braemar Shipping Jürgen Breuer Non-Executive Director Buy 6,000 6,000 First purchase
Brewin Dolphin Paul Wilson Director Buy 8,596 8,596  
Burberry Carolyn McCall Non-Executive Director Buy 1,117 undisclosed McCall also is CEO of easyJet
Bushveld Minerals Ian Watson Chairman Buy 540,000 undisclosed  
Crest Nicholson Steve Evans Production Director Sold 350,000 307,765 Same day as company reported profit increase
Daily Internet Michael Edelson Chairman Buy 6.3 million 27.6 million  
Daily Internet Christopher Evans CEO Buy 369,485 19.6 million  
Flybe Simon Laffin Chairman Buy 6,728 288,000 Same day as shares hit 14-month low
Foreign & Colonial Investment Trust  Christopher Keljik  Non-Executive Director Buy 9,000 72,001  
IG Group Stephen Hill Non-Executive Director Sold 42,000 79,324 Same day as Ex-dividend date
JPMorgan Smaller Cos Michael Quicke Chairman Buy 4.879 9,212  
JPMorgan Smaller Cos Andrew Robson Non-Executive Director Buy 1,000 2,163  
Learning Technologies Jonathan Satchell CEO Sold 3 million 110.2 million 11 days after saying  FY results to be ahead of expectations
Learning Technologies Leslie-Ann Reed Non-Executive Director Buy 750,000 750,000  
Learning Technologies Neil Elton Non-Executive Director Buy 160,000 160,000  
Kingfisher Ian Cheshire Director Sold 16,000 undisclosed Stood down as CEO on December, 8 2014
Kingfisher Kate Cheshire Spouse Sold 15,000 undisclosed  
Miton Group Gervais Williams MD Buy 295,000 9.1 million  
Porvair Raj Rajagopal Non-Executive Director Buy 15,000 15,000  
Proactis Sean McDonough COO Sold 100,000 121,666 Sold to other directors
Proactis Alan Aubrey Chairman Buy 25,000 1.1 million  
Proactis Rod Jones CEO Buy 25,000 1.9 million  
Proactis Tim Sykes CFO Buy 25,000 148,001  
Proactis Rodney Potts Non-Executive Director Buy 25,000 8.9 million  
ReNeuron Olav Hellebø CEO Buy 322,778 322,778  
ReNeuron Michael Hunt CFO Buy 161,556 1.5 million  
Telecom Plus Charles Wigoder Chairman Buy 25,000 16 million  
Telecom Plus Julian Schild Non-Executive Director Buy 25,000 158,682  
Telecom Plus Melvin Lawson Non-Executive Director Buy 25,000 2.1 million  
WYG Graham Olver COO Sold 23,404 1.9 million share options 2 days after WYG launched review into selling the company
WYG Louise Olver Spouse Sold 64,322 Nil  
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event.
When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam    
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.